

"REAL WORLD" EXPERIENCE OF TOFACITINIB AND BARICITINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: EFFECTIVENESS AND SAFETY EVALUATION

S. Garcia Garcia¹, I. Cardona Pascual¹, M. Larrosa Garcia¹, J.B. Montoro Ronsano¹, R. Caparros Ruiz², C. Alonso Martinez¹, J. Vidal Otero¹, S. Gamarra Calvo¹, M.R. Gómez Domingo¹, C. Alerany Pardo¹.

¹Pharmacy Service, ² Rheumatology Service, ³ Artificial Intelligence Information Service, Vall d'Hebron University Hospital, Barcelona, Spain

Purpose

Tofacitinib and baricitinib are approved for rheumatoid arthritis (RA) treatment. In pivotal clinical trials patients had higher DAS28-ESR than our patients and were less pre-treated with biologic Disease Modifying Antirheumatic Drugs (bDMARDs).

To assess effectiveness and safety of JKi in patients with RA in clinical setting.

Conclusion

Our study suggests that JKi could be effective in real-world settings after switching from other multiple bDMARDs.

Results showed a **modest benefit of JKi in complicated and over treated patients with diverse backgrounds**, as found in daily practice.

Results



53 patients

Mean age: 63.9 ± 13.3 years
46 (86.8 %) women.

Tofacitinib (TofG)

n= 44
83.0 %

Baricitinib (BarG)


n= 9
17.0 %

Previous non-biologic disease modifying antirheumatic drugs (non-bDMARDs) treatments

Methotrexate	n= 39	73.6 %
Leflunomide	n= 34	64.2 %
Hydroxychloroquine	n= 15	28.3 %
Sulfasalazine	n= 9	17.0 %

Previous biologic disease modifying antirheumatic drugs (bDMARDs) treatments

TofG	0	n= 7	15.9 %
	0 - 3	n= 22	50.0 %
	> 3	n=15	34.1 %
BarG	0	n= 2	22.2 %
	0 - 3	n= 3	33.3 %
	> 3	n= 4	44.4 %



At beginning of study...

Remission: n= 1
(1.9 %)

Mean DAS28-ESR: 4.97 ± 1.32

During monitoring period...

Remission: n= 9
(17.0 %)

Mean DAS28-ESR decrease: 0.69 ± 1.44 (10.3 ± 30.8 %), p<0.001

Tofacitinib (TofG): 0.64 ± 1.44 (9.3 ± 32.0 %)
Baricitinib (BarG): 0.98 ± 1.44 (15.6 ± 23.0 %)



Discontinued JKi

Baricitinib
(n= 3; 33.3 %)
Tofacitinib
(n= 9; 20.5 %)

Reasons of discontinuation:

	Baricitinib:	Tofacitinib:
Lack of effectiveness	n= 2; 22.2 %	n= 5; 9.4 %
Lack of adherence	n= 1; 11.1 %	n= 2; 3.8 %
Adverse effects	n= 0; 0 %	n= 1; 1.9 % (oedema, dyspnoea)
Patient's choice	n= 0; 0 %	n= 1; 1.9 %

Material and Methods

*Variance analysis(ANOVA) and Chi squared test were applied(SPSS®) to evaluate treatment effect(time=0 vs follow up data).




Observational retrospective study: 2016-2019




Patients with RA > 18 years old

"Patient and treatments registry program" of our local government

Clinical disease impact (analyzed variables)



Demographic, indication, previous and current treatments, discontinuity of treatment and reasons, effectiveness and safety data.



Disease activity score DAS28-ESR → Mean and standard deviation

Baseline and during follow up of JKi treatment

